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SARS, MERS AND COVID-19; the Story Continues 
 
From the beginning of millennium three, coronaviruses 
(SARS-CoV: 2003, MERS-CoV: 2012 and SARS-CoV-
2: 2019) emerged and caused outbreaks producing 
considerable global health problems. Although these 
three viruses have similarities especially regarding 
clinical features, there are key differences between them 
that limit the relevance of experiences from previous 
crises (1). SARS-CoV-2 replicates rapidly in respiratory 
epithelial cells, including the nasal cavity, bronchi, 
bronchioles, and alveoli. Replication in the upper 
respiratory tract results in transmission between hosts, 
while replication in the lower respiratory tract results in 
the development of lung disease. These three viruses are 
zoonotic ones which spread from animals and have a 
person to person transmission ability (2). AKI probably 
via direct renal cytotoxicity through DDP4 receptors 
which are largely represented in tubules and glomeruli is 
more frequent with MERS than the other two ones (3). 
COVID-19 generally has a less severe clinical picture, 
and because of higher R0 can spread in the community 
more easily than MERS and SARS, which has frequently 
been reported in the nosocomial setting. Allah Kalteh et 
al., in their report about mortality rate, case fatality rate, 
and years of potential life lost of these three viruses, 
showed that knowing this information is critical to 
characterize the severity and understand the pandemic 
potential of COVID-19 in the early stage of the epidemic. 
They confirmed that despite a lower fatality rate and 
because of the higher transmission rate of COVID-19, it 
causes a large number of infected patients and more 
deaths. They also showed that given that COVID-19 has 
a non-fatal effect on a large number of patients, the 
estimation of disease burden using the mentioned indices 
can be an appropriate way for future decision making 
regarding health policy (4). 
Physicians should notice that there are some 
differences between these three viruses regarding viral 
spread. The first one is the different viral tropism for the 
respiratory tract and the second can be different inoculum 
dose at the time of infection which defines the severity of 
the disease. Another point is the viral load at the time of 
symptom onset. In COVID-19, viral load progressively 
decreases during days but in SARS-CoV recorded highest 
after 10 days from symptom onset which proves much 
easier transmission of the virus during the initial mild 
symptomatic or even asymptomatic period (5, 6). Another 
important point is intrinsic virulence which is higher in 
MERS-CoV compared to others. This feature results in 
more severe clinical symptoms and hospital/ICU 
admission which reduces community transmission of the 
virus. Gastrointestinal involvement and diarrhea are more 
common in SARA especially in the Hong Kong outbreak 
and GI spread is also shown in MERS-CoV (7). As 
SARS-CoV can bind to the ACE2 receptor and replicate 
in the enteric epithelium, it can be the same for SARAV-
CoV-2 transmitting via this route (8). There are still many 
unanswered questions especially regarding its 
epidemiological features such as mortality and capacity to 
spread on a pandemic level. In the absence of a vaccine, 
we should notice that the speed of it spreads will depend 
on how conscientiously members of the public and 
hospital workers observe well-established infection 
prevention and control (IPC) principles—hand hygiene, 
cough etiquette, social distancing and, in healthcare 
settings, isolation of affected patients, and appropriate use 
of personal protective equipment (PPE). Using 
convalescent healthcare workers for the care of confirmed 
COVID-19 patients can be very important. Establishing 
national guidelines and revising them during the time are 
some of the most important responsibilities for the 
Ministry of Health and CDC. During the crisis, using 
telemedicine (9) can decrease the rate of transmission and 
appropriate use of social media can increase the social 
information regarding disease, pathogenesis, symptoms, 
transmission method, diagnosis, and treatment. Primary 
healthcare programs (e.g. maternal and child health, 
antenatal, and vaccination programs) during the crisis 
should cope with the ongoing waves of transmissions and 
ready for interventions that improve patients outcomes. 
As there is not an effective treatment for COVID-19, its 
early diagnosis and appropriate management of patients 
especially critically ill patients with COVID-19 are the 
cornerstones of its management (10, 11). Regarding 
treatment in the absence of a vaccine, it is recommended 
the first stage to use pharmaceuticals and their 
combinations (protease inhibitors, interferon compounds, 
antiviral antibodies) aiming to suppress diverse targets 
during virus propagation and the second disease stage, it 
seems crucial and reasonable to rely on the administration 
of pathogenetic drugs to restrict life-threatening events 
resulting in marked inflammation, intoxication, hypoxia, 
and infection (12). In future research, some aspects like 
microbiota/ microbiome, microRNAs, and mesenchymal 
stem cells should be considered as some potential 
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interventions. Future research should be focused on the 
biological properties of these viruses using virus 
isolation, reverse genetics, and in vitro and in vivo 
infection evaluations to help the prevention and control of 
the emerging crisis. The rapid spread of viruses from 
natural hosts to humans is largely due to human activities, 
including modern agricultural practices and urbanization. 
Therefore, the most important method to prevent viral 
zoonosis is to maintain the barriers between natural 
reservoirs and human society. Finally, we hope to be able 
to identify the most suitable approach to combat this 
crowned dragon as soon as possible and make this world 
a healthy place to live again. 
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Table1, Different characteristics of three types of coronavirus 
 SARS-CoV MERS-CoV SARS-Cov-2 
Phylogenic origin Clade I, Cluster IIb Clade II CladeI, Cluster IIa 
Animal reservoir bat bat bat 
Receptor ACE2 Dipeptdyl peptidase ACE2 
Mode of transmission Droplets spread from bats, 
which infected civets. Human to 
human transmission through 
close contact 
Droplets, touching infected 
camels, or eating their milk or 
meat. Limited human to human 
transmission through close 
contact 
Droplets, Touching, or eating an 
infected. Human-to-human 
transmission occurs through 
close contact 
Mean incub± period 5-6 days 2-7 days 7-14 days 
At-risk Elderly, med comorbid Elderly, med comorbid Elderly, med comorbid 
R0 1.7-1.9 0.7 1.5-3.5 
Treatment No specific No specific No specific 
Vaccine no no no 
ICU admission 23-34% 53-89% 24% 
ARDS * 20% 20-30% 18-30% 
AKI * 6.7% 40-50% 3% 
Mortality (Hospα patient) 3.6-15.7% 30-4-% 10-11% 
Overall Fatality 9% 34.4% 2-4% 
±: incubation period 
α: hospitalized patients 
*ARDS: acute respiratory distress syndrome; AKI: acute kidney injury 
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